<i>In vivo</i> treatment of a GEM model for sporadic CRC results in tumor regression.

<p>Mice with colonic tumors were randomized to treatment with control diluent (N = 8) or 45 mg/kg NVP-BEZ235 (N = 8) by daily oral gavage for 28 days. Resulting colonic tumor growth or regression was serially examined by optical colonoscopy. (A) Tumor Size Index (TSI) was calculated as Tumor Area (T) divided by Lumen Area (L) ×100. (B) Representative tumor colonoscopy still images during the 28 day treatment period. (C) Tumor volume of control and NVP-BEZ235-treated tumors at necropsy (mean 65 mm³ vs. 5 mm³; p = 0.01). (D) Final TSI vs. Tumor Volume (R² = 0.89, P<0.0001). Change in mean TSI for (E) control (32% pre-treatment vs. 57% post-treatment, P = 0.01) and (F) treated (32% vs. 20%, P = 0.02) cohorts.